Empirical Treatment and Prevention of COVID-19

키워드

참고문헌 (63)

1. "Coronavirus disease (COVID-19) situstion report -122"[URL]
2. Shang J, "Cell entry mechanisms of SARS-CoV-2", Proc Natl Acad Sci U S A, 117, pp.11727~11734 (2020)
3. Sigrist CJ, "A potential role for integrins in host cell entry by SARS-CoV-2", Antiviral Res, 177, pp.104759~ (2020)
4. Trilla A, "The 1918 “Spanish flu” in Spain", Clin Infect Dis, 47, pp.668~673 (2008)
5. Song Young Goo, "COVID-19, A Clinical Syndrome Manifesting as Hypersensitivity Pneumonitis", Infection and Chemotherapy, 52(1), pp.110~112 (2020), 대한감염학회[DOI]
6. Dakhama A, "Common respiratory viruses in lower airways of patients with acute hypersensitivity pneumonitis", Am J Respir Crit Care Med, 159, pp.1316~1322 (1999)
7. Zhen-Dong Y, "Clinical and transmission dynamics characteristics of 406 children with coronavirus disease 2019 in China: a review", J Infect (2020)
8. "COVID-19 treatment guidelines: coronavirus disease 2019 (COVID-19) treatment Guidelines"[URL]
9. Bessems JG, "Paracetamol(acetaminophen)-induced toxicity : molecular and biochemical mechanisms, analogues and protective approaches", Crit Rev Toxicol, 31, pp.55~138 (2001)
10. Misra DP, "Rheumatologists' perspective on coronavirus disease 19(COVID-19)and potential therapeutic targets", Clin Rheumatol, 39, pp.2055~2062 (2020)
11. Mori F, "A multicenter retrospective study on hypersensitivity Reactions to nonsteroidal anti-inflammatory drugs(NSAIDs)in children : a report fr : om the European Network on Drug Allergy(ENDA)group", J Allergy Clin Immunol Pract, 8, pp.1022~1031 (2020)
12. Caughey GE, "Roles of cyclooxygenase(COX)-1 and COX-2 in prostanoid production by human endothelial cells : selective up-regulation of prostacyclin synthesis by COX-2", J Immunol, 167, pp.2831~2838 (2001)
13. Mortensen R, "Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice", Commun Biol (2019)
14. Vasakova M, "Hypersensitivity pneumonitis : perspectives in diagnosis and management", Am J Respir Crit Care Med, 196, pp.680~689 (2017)
15. Wu Z, "Pseudoephedrine", ephedrine shows potent anti-inflammatory activity against TNF-α-mediated acute liver failure induced by lipopolysaccharide, Eur J Pharmacol, pp.2014, 724[DOI]
16. Muñoz-Cano RM, "Platelet-activating factor(PAF)in Allergic Rhinitis : Clinical and Therapeutic Implications", J Clin Med, 8, pp.1338~ (2019)
17. Frossard N, "Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine", Br J Clin Pharmacol, 65, pp.172~179 (2008)
18. Li Y, "Effects of perioperative cimetidine administration on peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer : results of a randomized controlled clinical trial", Hepatogastroenterology, 52, pp.504~508 (2005)
19. Pleasants RA, "Clinical pharmacology of oral maintenance therapies for obstructive lung diseases", Respir Care, 63, pp.671~689 (2018)
20. Park HK, "Altered gut microbiota by azithromycin attenuates airway inflammation in allergic asthma", J Allergy Clin Immunol, 145, pp.1466~1469 (2020)
21. Martinez MA, "Compounds with therapeutic potential against novel respiratory 2019 coronavirus", Antimicrob Agents Chemother, 64, pp.e00399~e00420 (2020)
22. Bouwman JJM, "Azithromycin reduces Chlamydia pneumoniae-induced attenuation of eNOS and cGMP production by endothelial cells", Eur J Clin Invest, 35, pp.573~582 (2005)
23. Arabi YM, "Treatment of middle east respiratory syndrome with a combination of lopinavir", ritonavir and interferon-β1b(MIRACLE trial) : statistical analysis plan for a recursive two-stage group sequential randomized controlled trial, 2020, pp.21, 8~
24. Kim Sun Bean, "Interim Guidelines on Antiviral Therapy for COVID-19", Infection and Chemotherapy, 52(2), pp.281~304 (2020), 대한감염학회[DOI]
25. Felsenstein S, "COVID-19 : Immunology and treatment options", Clin Immunol, 215, pp.108448~ (2020)
26. Diurno F, "Eculizumab treatment in patients with COVID-19 : preliminary results from real life ASL Napoli 2 Nord experience", Eur Rev Med Pharmacol Sci, 24, pp.4040~4047 (2020)
27. Mulangu S, "A randomized, controlled trial of ebola virus disease therapeutics", N Engl J Med, 381, pp.2293~2303 (2019)
28. Choy KT, "Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro", Antiviral Res, 178, pp.104786~ (2020)
29. Jean SS, "Treatment options for COVID-19 : The reality and challenges", J Microbiol Immunol Infect, 53, pp.436~443 (2020)
30. Elfiky AA, "Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study", Life Sci, 253, pp.117592~ (2020)
31. Härter G, "COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients", Infection (2020)
32. Sariyer IK, "Suppression of zika virus infection in the brain by the antiretroviral drug rilpivirine", Mol Ther, 27, pp.2067~2079 (2019)
33. Beck BR, "Predicting commercially available antiviral drugs that may act on the novel coronavirus(SARS-CoV-2)through a drug-target interaction deep learning model", Comput Struct Biotechnol J, 18, pp.784~790 (2020)
34. "Drug screening results by Korea Research Institute of Chemical Industry"[URL]
35. Shaw AC, "Age-dependent dysregulation of innate immunity", Nat Rev Immunol, 13, pp.875~887 (2013)
36. Cao B, "A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19", N Engl J Med, 382, pp.1787~1799 (2020)
37. Chu CM, "Role of lopinavir", ritonavir in the treatment of SARS : initial virological and clinical findings, 2004, pp.59, 252~256
38. Gautret P, "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial", Int J Antimicrob Agents (2020)
39. Hoffmann M, "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor", Cell, 181, pp.271~280.e8 (2020)
40. 양진호, "The impact of bacteria-derived ultrafine dust particles on pulmonary diseases", Experimental and Molecular Medicine, 52, pp.1~10 (2020), 생화학분자생물학회[DOI]
41. Zhou W, "Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia", Signal Transduct Target Ther, 5, pp.18~ (2020)
42. Zheng C, "Risk-adapted treatment strategy For COVID-19 patients", Int J Infect Dis, 94, pp.74~77 (2020)
43. Picchianti Diamanti A, "Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern : the fragile balance between infections and autoimmunity", Int J Mol Sci, 21, pp.3330~ (2020)
44. Tahir R, "A review of unfractionated heparin and its monitoring", US Pharm, 32, pp.HS-26~HS-36 (2007)
45. Dixon B, "Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients : a randomized controlled trial", Crit Care, 14, pp.R180~ (2010)
46. Balzarini J, "Inhibition of feline(FIPV)and human(SARS)coronavirus by semisynthetic derivatives of glycopeptide antibiotics", Antiviral Res, 72, pp.20~33 (2006)
47. Baron SA, "Teicoplanin: an alternative drug for the treatment of COVID-19?", Int J Antimicrob Agents, 55, pp.105944~ (2020)
48. Di Luigi L, "Sildenafil reduces expression and release of IL-6 and IL-8 induced by reactive oxygen species in systemic sclerosis fibroblasts", Int J Mol Sci, 21, pp.3161~ (2020)
49. Giesecke J, "The invisible pandemic", Lancet, 395, pp.e98~ (2020)
50. Hotez PJ, "COVID-19 vaccine design : the Janus face of immune enhancement", Nat Rev Immunol, 20, pp.347~348 (2020)
51. Prossegger J, "Effects of moderate mountain hiking and balneotherapy on community-dwelling older people : A randomized controlled trial", Exp Gerontol, 122, pp.74~84 (2019)
52. Brock DA, "Diversity of free-living environmental bacteria and their interactions with a bactivorous amoeba", Front Cell Infect Microbiol, 8, pp.411~ (2018)
53. Head K, "Saline irrigation for allergic rhinitis", Cochrane Database Syst Rev, 6, pp.CD012597~ (2018)
54. Elenius V, "The relationship of serum vitamins A, D, E and LL-37 levels with allergic status, tonsillar virus detection and immune response", PLoS One, 12, pp.e0172350~ (2017)
55. Sadarangani SP, "Non-anti-infective effects of antimicrobials and their clinical applications : a review", Mayo Clin Proc, 90, pp.109~127 (2015)
56. Ciavarella C, "Pharmacological(or Synthetic)and nutritional agonists of PPAR-γ as candidates for cytokine storm modulation in COVID-19 disease", Molecules, 25, pp.2076~ (2020)
57. Curtis N, "Considering BCG vaccination to reduce the impact of COVID-19", Lancet, 395, pp.1545~1546 (2020)
58. Kim S, "CRISPR RNAs trigger innate immune responses in human cells", Genome Res, 28, pp.367~373 (2018)
59. Baeten JM, "Antiretroviral prophylaxis for HIV prevention in heterosexual men and women", N Engl J Med, 367, pp.399~410 (2012)
60. Foster R, "Single-tablet emtricitabine-rilpivirine-tenofovir as HIV postexposure prophylaxis in men who have sex with men", Clin Infect Dis, 61, pp.1336~1341 (2015)
61. Tansey CM, "One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome", Arch Intern Med, 167, pp.1312~1320 (2007)
62. Lam MH, "Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors : long-term follow-up", Arch Intern Med, 169, pp.2142~2147 (2009)
63. 박완범, "Correlation between Pneumonia Severity and Pulmonary Complications in Middle East Respiratory Syndrome", Journal of Korean Medical Science, 33(24), pp.1~5 (2018), 대한의학회

관련 논문AI추천